Ira P. emails, I follow you every day, both on RealMoney and Twitter. I think you are the most objective, bar none! Can you please write about Cadence Pharmaceuticals (CADX)?
Cadence is hoping that FDA approves Ofirmev, an intravenous formulation of acetaminophen, on Nov. 4. For that to happen, FDA inspectors need to give the all clear to a Baxter (BAX) manufacturing plant where Ofirmev is made. "Market chatter" says FDA completed its plant re-inspection but Cadence, to date, hasn't confirmed publicly.
My sense is that investors largely expect the FDA to be assuaged by Baxter's remediation efforts at the Ofirmev manufacturing plant and that the drug will be approved on the Nov. 4 approval decision date. After that, I think opinions on mixed on the drug's commercial success.
Fan mail from Bob M.: "Your job is to write biased articles. You comment on stocks because it's fun. You have zero background in biotechnology, you have no medical or scientific credentials. Talk about leading lemmings over the cliff. Why would anyone believe a word that you say? TheStreet is certainly getting what they payed [sic] for, if they hired a stooge."More fan mail from Shantanu: "Aren't you a big fat lair [sic]? You lied before Vivus meeting and 85% of your lair [sic] hedge fund friends lied. How could you live with this type of unethical life?? Shame on you." One more fan letter, for fun. Asif A. gets creative, although he's punctuationally challenged: "You [BLEEP] can't see anybody else make money. And you are pretty ugly too. How is the woman situation with you?, probably not good. thats why you are writing stupid articles. O, lets do this. if Silenor becomes very successful, can we all come [BLEEP] you [BLEEP BLEEP BLEEP.] put your money where your mouth is, or should I say [BLEEP]. LOL" LOL, indeed.
Lastly, Adrian S. emails, "Really enjoy your articles. I sent you one email on this already and surprised you haven't jumped in on this yet. Labopharm (DDSS) looks to have a lot of promise at this juncture, having just launched Oleptro in the U.S. with their partner Angelini. With Canadian Oleptro approval and tramadol/acetaminophen combo approval in Europe by year's end I think it makes for an exciting near term story. What are your thoughts?" Not so fast, Adrian. Oleptro's U.S. launch isn't going well, even slower than expectations, which weren't all that high to begin with. And while the positive opinion from European regulators for the tramadol/acetaminophen combo is encouraging, launch is probably a year away and may be met with the same indifference there as tramadol. Labopharm is still a show-me stock. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV